Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act

Inhibrx is transitioning from a platform to a clinical-stage biotech, with ozekibart and INBRX-106 as key value drivers.
Investor's Business Daily on MSN

This once-deflated cloud stock deserves another look. Here's why.

A collaboration with Amazon and a potential breakout are just two of the factors putting Snowflake stock on investors' radar.